CD38 and Miyoshi myopathy: The inhibitory or enhancing effects of isatuximab and daratumumab on the hydrolase activity of CD38 molecules in MM cells [19, 21, 23, 40] and the potential in vivo impact on ADO production in MM patients remain to be further investigated and clarified [11].